In particular, mice were i.v. engrafted with Daudi FF-LUC cells on day −8 to allow a tumor burden to grow up to 107 level of bioluminescence (s/cm2/sr) before the i.v. infusion of either NT or CAR.CD19-T cells (10 × 106 cells per mouse) at day 0 (Fig. 5e shows the experimental design of the second in vivo model). The gene discussed is CD19; the disease is neoplasm.